80305

Drug test(s), presumptive, read by direct optical observation

CPT code 80305 represents the primary method for presumptive drug screening utilizing methods that are capable of being read by direct optical observation only. This process typically involves the use of immunoassay technologies integrated into testing devices such as dipsticks, cups, cards, or cartridges. Unlike definitive drug testing, which uses advanced methods like mass spectrometry to quantify specific substances and their metabolites, presumptive testing provides a qualitative result—either 'positive' or 'negative/non-detected'—for a specific drug class based on a predetermined cutoff concentration. Clinical laboratories and point-of-care settings utilize these tests to quickly screen for the presence of substances including, but not limited to, amphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiates, and tetrahydrocannabinol (THC). The procedure begins with the collection of a biological specimen, most commonly urine, followed by a validation check to ensure the sample's integrity, such as checking temperature, pH, or specific gravity. The sample is then introduced to the reagent-impregnated test strip. As the fluid migrates across the strip, antibodies react with specific drug metabolites. The results are interpreted visually by a healthcare professional by observing color changes or the appearance of lines in the test and control regions. Because 80305 is reported 'per date of service,' it includes all drug classes tested during that encounter. If a test results in a 'presumptive positive,' it may trigger a follow-up definitive test to confirm the identity and concentration of the substance. This code is critical for monitoring medication adherence in pain management or identifying potential substance use disorders in clinical, forensic, and emergency settings.

Clinical Indications

  • Monitoring compliance with prescribed controlled substance therapy (e.g., chronic pain management).
  • Screening for suspected substance use disorder or illicit drug use.
  • Evaluating patients with signs and symptoms of drug toxicity or overdose.
  • Pre-employment drug screening (though often non-covered by insurance).
  • Monitoring patients in addiction recovery programs.
  • Evaluation of altered mental status in emergency settings.
  • Neonatal drug screening for suspected prenatal exposure.

Procedure Steps

  1. Verify patient identity and obtain the biological specimen (typically urine) in a secure collection container.
  2. Perform specimen validation, including visual inspection and measurement of temperature within 4 minutes of voiding.
  3. Perform specimen validity testing if required (checking for pH, creatinine, or presence of oxidants) to ensure the sample has not been adulterated.
  4. Apply the specimen to the testing device (e.g., dipping the test strip or utilizing an integrated collection cup).
  5. Allow the specimen to react with the immunoassay reagents for the manufacturer-specified incubation time.
  6. Visually interpret the results by observing the presence or absence of specific lines or color changes in the test and control windows.
  7. Document the qualitative results (positive, negative, or invalid) for each drug class tested in the patient record.

Coding Guidelines

  • Report 80305 only once per date of service, regardless of the number of drug classes tested.
  • The code includes sample validation (e.g., pH, specific gravity) when performed; these cannot be billed separately.
  • Presumptive drug tests are categorized into three codes (80305, 80306, 80307) based on the method and complexity. 80305 is specifically for direct optical observation only.
  • For Medicare and Medicaid, use modifier -QW (CLIA-waived) if the laboratory holds a Certificate of Waiver and the specific device used is on the CLIA-waived list.
  • Do not report 80305 in conjunction with definitive drug testing codes (80320-80377) for the same drug classes unless the definitive test is performed as a follow-up to a presumptive result.
  • Presumptive drug testing (80305-80307) should not be used when definitive drug testing is the intended first-line procedure.

Associated ICD-10 Codes